J&J's Ry­bre­vant-chemo com­bo shows pos­i­tive PFS da­ta in con­fir­ma­to­ry study

John­son & John­son’s Ry­bre­vant met its pri­ma­ry end­point in a Phase III con­fir­ma­to­ry study test­ing the drug on pa­tients with new­ly di­ag­nosed ad­vanced or metasta­t­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER